Document is current

Article History

Accepted: 27 November 2021

First Online: 11 December 2021

Declarations

:

: No external funding was used in the preparation of this article.

: L. Lin, D. E. M. van Balen, and A. D. R. Huitema declare that they have no known competing financial interest or personal relationships that could have influenced the work reported in this paper. E. F. Smit reports a consulting or advisory role (institution) for AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Merck KGaA, MSD Oncology, Novartis, Roche/Genentech, Seattle Genetics, and Takeda; and research funding (institution) from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, and Roche/Genentech. A. J. de Langen reports grants from BMS, grants from MSD, grants from Boehringer, non-financial support from Merck Serono, grants from AstraZeneca, and non-financial support from Roche, outside the submitted work. J. H. Beijnen is a part-time employee and (indirect) shareholder of Modra Pharmaceuticals BV. He is (a part) patent holder of oral taxane formulations that are clinically developed by Modra Pharmaceuticals BV, a spin-off company of the Netherlands Cancer Institute, Amsterdam, the Netherlands. This is not related to this article.

: The conduct of this observational study was approved by the Investigational Review Board of the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital.

: The need for written consent for patients was waived per the above approval protocol.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors contributed to the study conception and design. Data collection and analysis were performed by L. Lin, A. D. R. Huitema, E. F. Smit, and A. J. De Langen. The first draft of the manuscript was written by L. Lin and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.